Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro does not come in a 1mg strength. The lowest available dose is 2.5mg, and that is where every course of treatment begins — no exceptions. If you have seen a reference to 1mg tirzepatide online, it is likely a mislabelled product, a search variant, or a sign of a counterfeit supply chain. As a prescription-only medicine, Mounjaro is only lawfully obtained following a clinical assessment by a registered prescriber, who confirms the correct dose for you before anything is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common reason people search for "1mg Mounjaro" is simple curiosity, they want to know whether an even lower starting point exists. It does not. Eli Lilly designed the 2.5mg dose specifically as a tolerability period. Its job is not to produce meaningful weight loss in the first four weeks; its job is to let your digestive system settle into the medicine before the dose goes up. Think of it as the body finding its feet.
This matters because tirzepatide slows gastric emptying and acts on two gut-hormone receptors simultaneously, GIP and GLP-1. Starting lower than the licensed schedule does not appear in the clinical evidence, and beginning at a higher dose to compensate for a missed step is associated with more pronounced nausea and GI discomfort. The NHS medicines page for tirzepatide describes the schedule clearly for patients who want to read the full picture.
A question our prescribers hear most weeks is whether the 2.5mg pen "does anything at all." The honest answer: for some people, a modest appetite reduction is noticeable even at this stage. For others, the change is subtle. Both are normal. The real work begins as the dose increases, and if you want to understand the full range of strengths available, the Mounjaro mg guide covers every step on the licensed schedule.
After four weeks at 2.5mg, the prescriber reviews your progress before approving a move to 5mg. That review is not a formality. It looks at tolerability (has the GI adjustment settled?), any changes to your health, and whether the clinical picture still supports continuing. At nume, this happens before every repeat order, a real prescriber reads your update, not software.
The full licensed schedule runs: 2.5mg → 5mg → 7.5mg → 10mg → 12.5mg → 15mg, with each step typically held for around four weeks. Not everyone reaches 15mg, and that is fine. Many people achieve the results they are looking for at an intermediate dose, and if you are considering what the second step involves specifically, the Mounjaro 5mg page explains what to expect when you move up from the starting dose. The prescriber decides the pace, not a calendar. If you are trying to understand the difference between what each step involves, the Mounjaro dose guide goes through each stage in detail.
Evidence from the SURMOUNT-1 trial, published in the New England Journal of Medicine, found that participants at 15mg achieved around 20–21% average body-weight reduction over 72 weeks. Outcomes varied at lower maintenance doses, which is why the prescriber's goal is to titrate to the highest dose you tolerate well, not simply the highest dose available.
If a seller is advertising Mounjaro at 1mg, 3mg, or any strength not on the licensed UK list (2.5, 5, 7.5, 10, 12.5, 15mg), treat that as a serious warning sign. The MHRA has confirmed that counterfeit tirzepatide pens are in circulation in the UK, a manufacturing site producing fake pens was raided in Northampton in October 2025, and enforcement in 2025 alone resulted in approximately 20 million doses of illegally traded weight-loss medicines (around £45m street value) being seized. Fake pens have been found to contain the wrong active substance entirely.
The safest check is straightforward: confirm any pharmacy you are considering is on the GPhC pharmacy register. You can also report a suspect seller directly through the MHRA Yellow Card scheme, which handles both side-effect reports and supply-chain concerns. A unlicensed dose strength combined with a price that feels too low is not a bargain, it is a pattern that precedes harm.
For a broader look at how Mounjaro works, the evidence behind it, and how to access it safely, the Mounjaro overview page covers the full picture. Separately, if cost is part of your thinking, the Mounjaro cost page explains what a legitimate private price actually includes.
Mounjaro is a prescription-only medicine, which means the conversation starts with a clinical assessment, not a shopping basket. At nume, that consultation is free. A GPhC-registered Independent Prescriber reviews your answers the same day (considering your BMI, health history, current medications and any contraindications) and decides whether Mounjaro is clinically suitable and, if so, at which strength to begin. The licensed starting point is always 2.5mg.
People who are not yet sure whether they meet the eligibility criteria can find a clear breakdown on the weight-loss treatments overview. The private licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as high blood pressure, high cholesterol or type 2 diabetes, though the prescriber assesses the full picture, not the number alone.
If you have questions about titration timing (when it is appropriate to move up a dose, and what signals suggest it is too soon) the dose-increase guide is the right place to start before speaking to a prescriber. Ready to take the first step? Speak to our prescribers through a free consultation and get a same-day clinical review.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.